12 analysts have expressed a variety of opinions on BioNTech (NASDAQ:BNTX) over the past quarter, offering a diverse set of opinions from bullish to bearish. In the table below, you’ll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Insights from analysts’ 12-month price targets are revealed, presenting an average target of $107.33, a high estimate of $113.00, and a low estimate of $85.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.23%. Interpreting …